Latest

Our top 10 videos of the year cover AI, innovation, compliance, and sustainability in biopharma.

FounderNest CEO Feliz Gonzalez breaks down where the biotech market stands today and where it’s headed in 2026

The top 10 BioPharm International articles of 2025 highlight policy shifts, manufacturing innovation, and strategic partnerships.

Autolomous and Trenchant’s partnership, begun early in 2025, addresses unmet CGT manufacturing needs, including slashing costs and cutting timelines.

In the first part of an extended video interview, Petra Dieterich and Jeffrey Mocny of Abzena emphasize that every part of the process of developing novel biologics is designed to bring them to humans not just quickly, but also safely.

A look at interchangeable biosimilars gaining FDA approval, the growth in global partnerships, and the rising biologics patent cliff.

Samsung Biologics’ Maryland acquisition signals a major push into US biologics manufacturing, reshaping the company’s capacity strategy and supply chain resilience.

$17.5M biopharma alliance leverages CAMP4's tech, addressin protein under-expression in haploinsufficient disorders

EMA Director sees new legislation as an opportunity to revamp policies.

In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates (RCA), and Siegfried Schmitt, Parexel, tackle the ever-growing problem of having a properly trained workforce with a variety of needed skill sets.

This past year in biologics was marked by clinical trends, manufacturing scalability, and regulatory acceleration for antibody therapeutics.

Norgine has gained regional rights to Vir Biotechnology’s hepatitis delta drug pairing, strengthening late-stage antiviral development across Europe, Australia, and New Zealand.

In Episode 30, John Androsavich, Benjamin Fryer, and John Wilkerson go behind the headlines.